Torrent Pharmaceuticals Ltd · NSE:TORNTPHARM
Torrent Pharmaceuticals — Q1 FY2015 Earnings Presentation
23 slides from Torrent Pharmaceuticals's earnings presentation, 2014
Slide 1: Investor Presentation Q1 FY 2014-15
Investor Presentation Q1 FY 2014-15 1
Slide 2: Caveat
Caveat This information may contain certain forward-looking statements/ details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expre
Slide 3: Agenda
AGENDA Performance over Period Highlights – Q1 FY 15 Segmental Highlights Shareholding Pattern 3
Slide 4: Performance Over Period
torrent PHARMA Performance Over Period
Slide 5: Torrent Pharma: Assets Across the Value Chain
Torrent Pharma: Assets Across the Value Chain Domestic Sales Research and International Manufacturing and Acquisition Development Operations Marketing Value-added API + formulation Broad and Reach to over 70 Acquired generics facilities having differentiated countries with 17 Identified pa
Slide 6: Quarterly Performance
Quarterly Performance 2 ,0 0 0 2 0 ,0 0 256 244 1 ,8 0 0 1 8 ,0 0 349 1 ,6 0 0 1 6 ,0 0 317 1 ,4 0 0 158 1 4 ,0 0 149 113 1,225 12,007 1 ,2 0 0 188 1 2 ,0 0 187 152 1,114 1,015 1 ,0 0 0 972 1 0 ,0 0 972 8,860 8 0 0 8,021 8 ,0 0 0 6,952 7,392 6 0 0 6 ,0 0 0 4 0 0 4 ,0 0 0 Q1 13-14 Q2 13-14 Q3 13-14 Q
Slide 7: Highlights – Q1 FY 15
torrent PHARMA Highlights - Q1 FY 15
Slide 8: Q1 FY15 Performance Highlights
Q1 FY15 Performance Highlights • Revenues at ` 1,114 Cr vs. ` 972 Cr, growing at 15%; • India formulation market growing at 13% & • International operations growing at 36%; Constant currency growth of 27% • USA & European markets key contributors to growth • PBT at ` 349 Cr vs. ` 187 Cr in Q1 FY 14;
Slide 9: Revenue Progression
Revenue Progression ` Cr Particulars Q1 Q1 13-14 12-13 14 - 15 13 - 14 India (A) 352 312 1,161 1,024 Gwth % 13% 13% 13% International (B) 733 539 2,629 1,827 Gwth % 36% 44% 44% Total (A+B) 1,085 852 3,791 2,852 Gwth % 27% 33% 31% USA 269 113 776 355 Brazil 149 133 533 502 Europe 230 196 930 650 ROW
Slide 10: P&L
P&L ` Cr Q1 Q1 P a rtic ula r s 1 3 -1 4 1 2 -1 3 14 - 15 13 - 14 Re ve nue s 1 ,1 1 4 972 4 ,1 8 4 3 ,2 1 2 C OGS 301 299 1 ,2 3 8 926 % R e v e nue s 27% 31% 30% 29% S G& A S p e n d 284 280 1 ,1 6 9 965 % R e v e nue s 25% 29% 28% 30% E m p lo ye e C o s t 184 172 741 623 % R e v e nue s 17% 18%
Slide 11: Balance Sheet
Balance Sheet ` Cr Particulars 31-Mar-14 % 30-Jun-14 % ∆ EQUITY AND LIABILITIES Shareholders funds 1,902 66% 2,180 47% 277 Minority Interest 0 0% 0 0% 0 Non-current liabilities 992 34% 2,466 53% 1,473 TOTAL 2,895 100% 4,646 100% 1,750 ASSETS Net Fixed Assets 1,409 49% 3,469 75% 2,060 Goodwill On Con
Slide 12: Segmental Highlights
torrent PHARMA Segmental Highlights
Slide 13: Business Segment: India
Business Segment : India 13
Slide 14: Synergies – Elder Acquisition
Synergies – Elder Acquisition SCALE Shelcal & Chymoral brands FOCUS command strong equity in New divisions in Pain & the respective therapies VMN focus – Further Ranked 16th in market extending the TPL specialty (From 20th) focus approach into new specialties Entry into top 10 specialty cos. Shelcal
Slide 15: India
India ` Cr Q1 Q1 India 13-14 12-13 14 - 15 13 - 14 Revenues 352 312 1161 1024 % Growth 13% 13% Q1 FY 15 Highlights • IPM growth MAT Jun-14: 7%, Covered Market growth: 6%, Torrent growth: 15% Growth drivers • Continuing Brand building through specialty focus & scientific focus in all divisions. • Out
Slide 16: Business Segment: International
Business Segment : International 16
Slide 17: USA
USA ` Cr Q1 Q1 USA 13-14 12-13 14 - 15 13 - 14 Revenues 269 113 776 355 % Growth 138% 119% Q1 FY 15 Highlights • Constant Currency Growth 118%, driven by New Products. Growth drivers • As of Jun-14 the Company has 48 ANDA approvals (including 5 tentative approvals) and its pipeline consists of 22 pe
Slide 18: Brazil
Brazil ` Cr Q1 Q1 Brazil 13-14 12-13 14 - 15 13 - 14 Revenues 149 133 533 502 %Growth 12% 6% Q1 FY 15 Highlights • Constant currency Growth 13% • Covered Market Growth (excluding Government reimbursement programme) is 12%, Torrent growth 17% as per IMS in units term. Growth drivers • Pipeline : 13 p
Slide 19: Europe
Europe ` Cr Q1 Q1 Europe 13-14 12-13 14 - 15 13 - 14 Revenues 230 196 930 650 % Growth 17% 43% Q1 FY 15 Highlights • Constant currency growth 3% • Germany Operations are the key contributors to the growth Growth drivers • New Products going off patent and Therapy coverage expansion in Heumann • Grow
Slide 20: ROW
ROW ` Cr Q1 Q1 ROW 13-14 12-13 14 - 15 13 - 14 Revenues 86 97 388 328 % Growth -12% 18% Q1 FY 15 Highlights • Revenue de growth due to: • Market Inventory correction & • Discontinuation of sales in non performing countries. Growth drivers • Middle East/ Africa Region Delivering the growth being an u
Slide 21: Shareholding Pattern
torrent PHARMA Shareholding Pattern
Slide 22: Shareholding Pattern as on June 30, 2014
Shareholding Pattern; as on June 30, 2014 • Total shares outstanding : 16.92 crores • Free Float (shares) : 4.82 crores Individual & others Mutual 8% Funds 7% FIIs 13% Promoter & Promoter group 72% CAGR Return of more than 20% since IPO 22
Slide 23: Thank You
Thank You 23
Torrent Pharmaceuticals — Q1 FY2015 Earnings Presentation on 6ix